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Niacin-Induced Clotting Factor Synthesis
Deficiency With Coagulopathy
Brian D. Dearing, MD; Carl J. Lavie, MD; Thomas P. Lohmann, MD; Edward Genton, MD
Although coagulopathy is a well-known complication of
severe niacin-induced hepatotoxic reaction, it is not found
in patients with minimal aminotransferase level elevations.
Three patients with significant clotting factor synthesis de-
ficiency and coagulopathy (prothrombin times, >1.5 times
control) from sustained-release niacin had only mild ami-
notransferase level elevations (1.5 to 2.0 times normal). In
each case, protein deficiency, coagulopathy, and ami-
notransferase level elevation resolved promptly after with-
drawal of niacin therapy. In one case, this syndrome
recurred after rechallenge with sustained-release niacin,
whereas the coagulopathy did not recur in a second patient
rechallenged with crystalline niacin. Deficiency in protein
synthesis, including coagulation factors, and coagulopathy
are unrecognized complications of sustained-release niacin
therapy. These cases indicate the need to measure pro-
thrombin times routinely in patients who develop even mild
aminotransferase level elevation while receiving sustained-
release niacin therapy. These data are important in light of
the increasing use of sustained-release niacin in the treat-
ment of patients with lipid disorders.(Arch Intern Med. 1992;152:861-863)
During the past two decades, the lipid-coronary heartdisease (CHD) hypothesis has become better estab¬
lished. Therefore, greater efforts are being directed at
both nonpharmacologic and drug treatment of lipid dis¬
orders, particularly elevated levels of total cholesterol and
low-density lipoprotein cholesterol. ' Epidemiologie, lipid
intervention, and coronary angiographie studies have
also documented the pivotal role of high-density tipopro-
tein cholesterol for assessing CHD risk, with considerable
data suggesting that this lipoprotein may be the best lipid
predictor of CHD.210
Niacin (nicotinic acid), a water-soluble B vitamin, may
be an ideal lipid-lowering agent, since it is relatively inex¬
pensive and has beneficial effects in most patients with
dyslipidemias. Niacin therapy has been shown to be as¬
sociated with reduced CHD events and reduced progres¬
sion of coronary artery disease by angiography,11,12 and it
is the only lipid-lowering drug to be associated with
long-term reduction in total mortality.4,5 Its mechanism of
action is not completely understood, but it significantly
reduces levels of total cholesterol, low-density lipoprotein
cholesterol, and triglycérides as well as increases the level
of high-density lipoprotein.12,13 The hypolipidemic effect
is thought to result from a decrease in synthesis of very-
low-density lipoprotein particles (which are formed in
hepatocytes and from which low-density Upoprotein
cholesterol is derived) and inhibition of stimulation of li-
polysis.14 Although niacin therapy may be limited by
troublesome short-term adverse effects, they are usually
not life threatening, and the long-term safety is well es¬
tablished. Sustained-release preparations of niacin de¬
crease the incidence of side effects and improve compU-
ance and, therefore, are becoming more popular. While
niacin therapy has been associated with hepatotoxic
effects,15"25 there is no documentation of niacin-induced
alterations in clotting factor synthesis or coagulopathy
without significant hepatotoxic effects. In the present re¬
port, we present three cases of niacin-induced significant
coagulopathy secondary to clotting factor deficiency, with
minimal evidence of hepatotoxic reaction.
REPORT OF CASES
Case 1.—A 55-year-old man with known coronary artery dis¬
ease and hyperlipidemia presented with crescendo angina.
Medications at the time of admission included sustained-release
diltiazem hydrochloride, 90 mg twice a day; aspirin once a day;
and sustained-release niacin, 1000 mg twice a day (which had
been started 3 months earlier).
Admission laboratory tests revealed a coagulopathy (pro-
thrombin time [PT] of 17.2 seconds with a control of 11.3
seconds) with minimal aminotransferase level elevation (Table).
Mixing studies disclosed a factor deficiency. The niacin was dis¬
continued, and the prothrombin time slowly improved. Results
of laboratory tests repeated 14 days later were normal. The pa¬
tient was rechaUenged with niacin, 500 mg twice a day for 1
week, then 1000 mg twice a day; 11 days later, his PT was 19.3
seconds (control, 11.3 seconds). The niacin was again discontin¬
ued, and after 5 days his PT and liver enzyme levels were nor¬
mal.
Case 2.—A 47-year-old man with coronary artery disease, hy¬
perlipidemia, and a remote history of inactive non-A, non-B
hepatitis presented with unstable angina pectoris. Medications
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Laboratory Values in Three Patients With Niacin-induced Clotting Factor Synthesis Deficiency and Coagulopathy*
Total HDL-C,
Albumin, Bilirubin, TC, mmol/L TG, mmol/L mmol/L
grt. u.mol/L AST, U/L ALT, U/L (mg/dL) (mg/dL) (mg/dL) PT, s PTT, s
Normal values 35-55 1.7-17.1 0-37 0-40 3.10-5.15 0.63-3.15 0.98-1.63 11.3+ 29.8t
(120-199) (38-63)
Patient 1
Baseline 47 17.1 22 28 6.00(232) 1.14 1.16(45) .
Acute presentation* 35 12.0 55 86 3.96 (153) 0.40 . . . 17.2 33.7
Recovery! 45 8.6 19 17 5.69(220) 0.75 1.16(45) 12.2 24.9
RechallengeH • • • • • • • • • • • • • • • • • • • • • 19-3
Patient 2
Baseline 47 8.6 14 24 6.18(239) 1.81 ... .
Acute presentationU 32 10.3 65 56 1.66(64) 0.59 ... 19.2 36.8
Recovery! 44 10.3 17 15 4.63(179) 1.32 0.65(25) 11.4
Rechallenge# 48 15.4 31 37 5.20(201) 0.89 1.01(39) 11.9
Patient 3
Baseline ... ... 17 ... 4.76 (184) 1.51 0.65 (25) .
Acute presentation** 38 12.0 73 56 2.97 (115) 0.41 . . . 17.7 33.1
Recovery! 47 12.0 18 18 4.14 (160) 0.93 0.57 (22) 12.6 27.6
*ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; HDL-C, high-density lipoprotein cholesterol; PT, prothrom-
bin time; PTT, partial thromboplastin time; TC, total cholesterol; and TG, triglycérides.
tControl mean.
4Slo-Niacin, 1000 mg twice daily for 3 months.§AII follow-up laboratory work 2 to 3 weeks after discontinuing niacin.||Slo-Niacin, 1000 mg twice daily for 2 weeks.
IISR-Niacin, 1000 mg three times daily for 10 months.
#Crystalline niacin, 1000 mg twice daily for 3 months.
**Slo-Niacin, 1000 mg three times daily for 5 weeks.
at this time included one aspirin tablet daily and sustained-
release niacin, 1000 mg twice a day.
Initial laboratory tests (Table) revealed mild aminotransferase
level elevation with a coagulopathy (PT, 19.2 seconds with a
control of 11.5 seconds). An abdominal computed tomographic
scan was performed to exclude malignant neoplasm, in light of
low plasma cholesterol and albumin levels; the hepatic size was
normal, with homogeneous parenchyma.
The niacin was discontinued and phytonadione was adminis¬
tered; the PT normalized over approximately 2 days. Follow-up
laboratory values were within normal limits. The subject was
then rechallenged with crystalline niacin and, after 4 months,
had not developed any laboratory abnormalities.
Case 3. —A 44-year-old man with known coronary artery dis¬
ease presented with exertional angina. His medications at the
time of admission were sustained-release diltiazem hydrochlo-
ride, 120 mg twice a day; aspirin once a day; and sustained-
release niacin, 1000 mg three times a day (for 5 weeks).
Laboratory studies at admission (Table) disclosed a coagulop¬
athy (PT, 17.7 seconds with a control of 11.3 seconds), again with
only mild aminotransferase level elevation. Qualitative factor
assays obtained during the acute presentation demonstrated
markedly decreased factor VII (20%) and borderline decreased
factor II (51%) levels but normal factor IX and X levels. Quanti¬
tative immunologie factor assay showed a proportional reduc¬
tion in the level of factor VII (14%).
The niacin was discontinued, and the laboratory values
returned to normal. Functional factor assays repeated at 2 weeks
demonstrated a mildly reduced factor VII level of 40% and a
normal factor II level of 92%.
COMMENT
The incidence and mechanism of niacin-induced hepa¬
totoxic reaction are not known.15"26 Biopsy specimens have
demonstrated cholestatic changes with cell necrosis and
portal fibrosis.16 Fulminant hepatic failure may rarely oc¬
cur with niacin treatment.17,18 Typically, significant hepa¬
totoxic reaction occurs with high doses (&3 g/d) given for
prolonged periods,16 indicating a need for monitoring
aminotransferase values in patients receiving niacin ther¬
apy.2 In niacin-treated patients with hepatotoxic reac¬
tions, it is not unusual to find markedly prolonged
PTs,15"25 but this coagulopathy is associated with a greater
than threefold elevation in hepatic aminotransferase val¬
ues and a greater than twofold elevation in bilirubin lev¬
els. In the present cases, however, the coagulopathy oc¬
curred out of proportion to the aminotransferase level
elevation (Table) and without hyperbilirubinemia, but it
was associated with reduced levels of albumin and
lipoproteins. This is an important observation, since it is
common to monitor only the aminotransferase values af¬
ter initiating niacin therapy, and a mild elevation in such
a nonspecific test may not suggest significant drug-induced toxic reaction.
The mechanism of this niacin-induced coagulopathy is
not clear and may represent a different pathophysiology
than that of typical niacin-induced hepatitis. The associ¬
ated laboratory abnormalities (Table), such as decreased
albumin levels and markedly decreased levels of plasma
cholesterol and triglycérides, with mildly elevated ami¬
notransferase values, suggest a mechanism of decreased
synthesis27 rather than hepatoceUular injury. The quanti¬
tative decrease in factor VII level seen in patient 3 is also
consistent with altered protein synthesis and estabhshes
that the effect is not from qualitative changes in clotting
factors, as is seen with vitamin K deficiency or warfarin
therapy. It is not known if this is secondary to effects on
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hepatocyte secretion or a more basic biochemical mecha¬
nism affecting protein synthesis. In addition, our patients
were all taking moderate doses (3=2 g/d) of a sustained-
release formula of niacin at the time of presentation, and
patient 2 was rechallenged with crystalline niacin without
recurrence of the coagulopathy. This raises the question
of whether this phenomenon is secondary to nicotinic
acid or is peculiar to the sustained-release preparation.
National attention is currently directed at Upids,1 and
recent evidence suggests that low levels of high-density
lipoprotein cholesterol are the predominant lipid abnor¬
mality in most patients with CHD.2,3,6,8,9 In addition, pre¬
liminary data indicate that sustained-release niacin ther¬
apy is extremely effective in patients with CHD who have
"isolated" low levels of high-density lipoprotein choles¬
terol.10 These factors make it likely that the use of niacin
therapy will increase. Our data suggest that prothrombin
times should be monitored in patients who develop even
mild aminotransferase level elevations or depressed li¬
poprotein levels while taking sustained-release prepara¬
tions of niacin. The recognition of this coagulopathy in
patients with trivial to mild aminotransferase level eleva¬
tion is important, since, according to the manufacturer,
niacin may activate peptic ulcer disease, and cardiac pa¬
tients taking this drug are at risk for invasive vascular
procedures. Also, patients taking oral anticoagulants
should be closely monitored for markedly prolonged
prothrombin times, since this abnormality may potentiate
the effect of the drug.
Further studies will be required to determine the
prevalence and exact mechanism of this niacin-induced
clotting factor synthesis deficiency and coagulopathy,
as well as the relative risk with the use of various
niacin preparations. Also, the issue of selective vs gen¬
eral alteration of clotting factors and protein synthesis
needs to be clarified.
We thank Leda L. Lupo for preparing and editing the manuscript.
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